10-Q Filing

CVS HEALTH CORP CIK: 64803 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0000064803-22-000029`
Period End Date	20220630
Filing Date	20220803
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	cvs-20220630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 101 Income Statement 82 Cash Flow Statement 84 Stockholders Equity 58 Comprehensive Income 40

Balance Sheet 101 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	100,000.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$12.12B	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	100,000.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.41B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.12B	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Investments	`ShortTermInvestments`	$2.88B	USD	Point-in-time
Investments	`ShortTermInvestments`	$3.12B	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$27.23B	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$24.43B	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Inventories	`InventoryNet`	$17.38B	USD	Point-in-time
Inventories	`InventoryNet`	$17.76B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$2.54B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$5.29B	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	3.20B	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	3.20B	shares	Point-in-time
Total current assets	`AssetsCurrent`	$60.01B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$62.14B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	1.75B	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	1.74B	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.32B	shares	Point-in-time
Long-term investments	`LongTermInvestments`	$21.12B	USD	Point-in-time
Long-term investments	`LongTermInvestments`	$23.02B	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.31B	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$12.76B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$12.90B	USD	Point-in-time
Treasury stock (in shares)	`TreasuryStockShares`	443.00M	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockShares`	422.00M	shares	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$19.12B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$18.56B	USD	Point-in-time
Goodwill	`Goodwill`	$79.12B	USD	Point-in-time
Goodwill	`Goodwill`	$78.56B	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$28.14B	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$29.03B	USD	Point-in-time
Separate accounts assets	`SeparateAccountAssets`	$5.09B	USD	Point-in-time
Separate accounts assets	`SeparateAccountAssets`	$4.14B	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$4.85B	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$4.71B	USD	Point-in-time
Total assets	`Assets`	$233.00B	USD	Point-in-time
Total assets	`Assets`	$230.28B	USD	Point-in-time
Accounts payable	`AccountsPayableTradeCurrent`	$13.24B	USD	Point-in-time
Accounts payable	`AccountsPayableTradeCurrent`	$12.54B	USD	Point-in-time
Pharmacy claims and discounts payable	`PharmacyClaimsandDiscountsPayableCurrent`	$17.33B	USD	Point-in-time
Pharmacy claims and discounts payable	`PharmacyClaimsandDiscountsPayableCurrent`	$18.39B	USD	Point-in-time
Health care costs payable	`LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet`	$8.81B	USD	Point-in-time
Health care costs payable	`LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet`	$10.40B	USD	Point-in-time
Policyholders funds	`OtherPolicyholderFunds`	$1.63B	USD	Point-in-time
Policyholders funds	`OtherPolicyholderFunds`	$4.30B	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$17.67B	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$17.73B	USD	Point-in-time
Other insurance liabilities	`OtherInsuranceLiabilitiesCurrent`	$1.20B	USD	Point-in-time
Other insurance liabilities	`OtherInsuranceLiabilitiesCurrent`	$1.30B	USD	Point-in-time
Current portion of operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.85B	USD	Point-in-time
Current portion of operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.65B	USD	Point-in-time
Current portion of long-term debt	`LongTermDebtAndCapitalLeaseObligationsCurrent`	$4.02B	USD	Point-in-time
Current portion of long-term debt	`LongTermDebtAndCapitalLeaseObligationsCurrent`	$4.21B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$67.81B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$68.46B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$18.18B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$17.50B	USD	Point-in-time
Long-term debt	`LongTermDebtAndCapitalLeaseObligations`	$50.80B	USD	Point-in-time
Long-term debt	`LongTermDebtAndCapitalLeaseObligations`	$51.97B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$6.27B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$5.45B	USD	Point-in-time
Separate accounts liabilities	`SeparateAccountsLiability`	$5.09B	USD	Point-in-time
Separate accounts liabilities	`SeparateAccountsLiability`	$4.14B	USD	Point-in-time
Other long-term insurance liabilities	`OtherInsuranceLiabilitiesNoncurrent`	$6.29B	USD	Point-in-time
Other long-term insurance liabilities	`OtherInsuranceLiabilitiesNoncurrent`	$6.40B	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.90B	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.14B	USD	Point-in-time
Total liabilities	`Liabilities`	$157.62B	USD	Point-in-time
Total liabilities	`Liabilities`	$154.77B	USD	Point-in-time
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.01: 3,200 shares authorized; 1,755 shares issued and 1,312 shares outstanding at June 30, 2022 and 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and capital surplus	`CommonStocksIncludingAdditionalPaidInCapital`	$47.38B	USD	Point-in-time
Common stock, par value $0.01: 3,200 shares authorized; 1,755 shares issued and 1,312 shares outstanding at June 30, 2022 and 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and capital surplus	`CommonStocksIncludingAdditionalPaidInCapital`	$47.87B	USD	Point-in-time
Treasury stock, at cost: 443 shares at June 30, 2022 and 422 shares at December 31, 2021	`TreasuryStockValue`	$28.17B	USD	Point-in-time
Treasury stock, at cost: 443 shares at June 30, 2022 and 422 shares at December 31, 2021	`TreasuryStockValue`	$30.41B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$58.71B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$54.91B	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$965.00M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-988.00M	USD	Point-in-time
Total CVS Health shareholders equity	`StockholdersEquity`	$75.08B	USD	Point-in-time
Total CVS Health shareholders equity	`StockholdersEquity`	$75.18B	USD	Point-in-time
Noncontrolling interests	`MinorityInterest`	$322.00M	USD	Point-in-time
Noncontrolling interests	`MinorityInterest`	$306.00M	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$75.51B	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$69.70B	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$74.14B	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$73.56B	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$71.16B	USD	Point-in-time
Total shareholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$75.38B	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$233.00B	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$230.28B	USD	Point-in-time

Income Statement 82 line items

Line Item	Tag	Value	Unit	Period
Premiums	`PremiumsEarnedNet`	$18.98B	USD	1 Quarter
Premiums	`PremiumsEarnedNet`	$21.26B	USD	1 Quarter
Premiums	`PremiumsEarnedNet`	$42.89B	USD	2 Qtrs
Premiums	`PremiumsEarnedNet`	$37.94B	USD	2 Qtrs
Net investment income	`NetInvestmentIncome`	$586.00M	USD	2 Qtrs
Net investment income	`NetInvestmentIncome`	$289.00M	USD	1 Quarter
Net investment income	`NetInvestmentIncome`	$146.00M	USD	1 Quarter
Net investment income	`NetInvestmentIncome`	$314.00M	USD	2 Qtrs
Total revenues	`Revenues`	$72.62B	USD	1 Quarter
Total revenues	`Revenues`	$141.71B	USD	2 Qtrs
Total revenues	`Revenues`	$157.46B	USD	2 Qtrs
Total revenues	`Revenues`	$80.64B	USD	1 Quarter
Cost of products sold	`CostOfGoodsAndServicesSold`	$49.29B	USD	1 Quarter
Cost of products sold	`CostOfGoodsAndServicesSold`	$94.80B	USD	2 Qtrs
Cost of products sold	`CostOfGoodsAndServicesSold`	$43.52B	USD	1 Quarter
Cost of products sold	`CostOfGoodsAndServicesSold`	$84.41B	USD	2 Qtrs
Benefit costs	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$31.61B	USD	2 Qtrs
Benefit costs	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$15.90B	USD	1 Quarter
Benefit costs	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$17.61B	USD	1 Quarter
Benefit costs	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$35.56B	USD	2 Qtrs
Operating expenses	`OperatingExpenses`	$17.79B	USD	2 Qtrs
Operating expenses	`OperatingExpenses`	$9.17B	USD	1 Quarter
Operating expenses	`OperatingExpenses`	$19.05B	USD	2 Qtrs
Operating expenses	`OperatingExpenses`	$8.87B	USD	1 Quarter
Total operating costs	`CostsAndExpenses`	$76.07B	USD	1 Quarter
Total operating costs	`CostsAndExpenses`	$149.40B	USD	2 Qtrs
Total operating costs	`CostsAndExpenses`	$133.81B	USD	2 Qtrs
Total operating costs	`CostsAndExpenses`	$68.29B	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$4.33B	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$8.06B	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$7.90B	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$4.57B	USD	1 Quarter
Interest expense	`InterestExpense`	$583.00M	USD	1 Quarter
Interest expense	`InterestExpense`	$1.29B	USD	2 Qtrs
Interest expense	`InterestExpense`	$1.17B	USD	2 Qtrs
Interest expense	`InterestExpense`	$636.00M	USD	1 Quarter
Other income	`OtherNonoperatingIncomeExpense`	$43.00M	USD	1 Quarter
Other income	`OtherNonoperatingIncomeExpense`	$85.00M	USD	2 Qtrs
Other income	`OtherNonoperatingIncomeExpense`	$45.00M	USD	1 Quarter
Other income	`OtherNonoperatingIncomeExpense`	$95.00M	USD	2 Qtrs
Income before income tax provision	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.03B	USD	1 Quarter
Income before income tax provision	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$3.73B	USD	1 Quarter
Income before income tax provision	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$6.71B	USD	2 Qtrs
Income before income tax provision	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$6.97B	USD	2 Qtrs
Income tax provision	`IncomeTaxExpenseBenefit`	$1.69B	USD	2 Qtrs
Income tax provision	`IncomeTaxExpenseBenefit`	$944.00M	USD	1 Quarter
Income tax provision	`IncomeTaxExpenseBenefit`	$1.07B	USD	1 Quarter
Income tax provision	`IncomeTaxExpenseBenefit`	$1.70B	USD	2 Qtrs
Net income	`ProfitLoss`	$5.27B	USD	2 Qtrs
Net income	`ProfitLoss`	$5.01B	USD	2 Qtrs
Net income	`ProfitLoss`	$2.31B	USD	1 Quarter
Net income	`ProfitLoss`	$2.96B	USD	1 Quarter
Net income	`ProfitLoss`	$2.79B	USD	1 Quarter
Net income	`ProfitLoss`	$2.22B	USD	1 Quarter
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$8.00M	USD	1 Quarter
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$10.00M	USD	1 Quarter
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$11.00M	USD	2 Qtrs
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$9.00M	USD	2 Qtrs
Net income attributable to CVS Health	`NetIncomeLoss`	$2.95B	USD	1 Quarter
Net income attributable to CVS Health	`NetIncomeLoss`	$5.01B	USD	2 Qtrs
Net income attributable to CVS Health	`NetIncomeLoss`	$2.78B	USD	1 Quarter
Net income attributable to CVS Health	`NetIncomeLoss`	$5.26B	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$2.11	USD	1 Quarter
Basic (in dollars per share)	`EarningsPerShareBasic`	$4.01	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$3.80	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$2.25	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$3.78	USD	2 Qtrs
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$3.97	USD	2 Qtrs
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$2.23	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$2.10	USD	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.31B	shares	2 Qtrs
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.32B	shares	2 Qtrs
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.31B	shares	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.32B	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.32B	shares	2 Qtrs
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.32B	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.32B	shares	2 Qtrs
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.33B	shares	1 Quarter
Dividends declared per share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$0.55	USD	1 Quarter
Dividends declared per share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$0.50	USD	1 Quarter
Dividends declared per share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$1.00	USD	2 Qtrs
Dividends declared per share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$1.10	USD	2 Qtrs

Cash Flow Statement 84 line items

Line Item	Tag	Value	Unit	Period
Cash receipts from customers	`ProceedsFromCustomers`	$151.77B	USD	2 Qtrs
Cash receipts from customers	`ProceedsFromCustomers`	$136.62B	USD	2 Qtrs
Cash paid for inventory and prescriptions dispensed by retail network pharmacies	`PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies`	$79.32B	USD	2 Qtrs
Cash paid for inventory and prescriptions dispensed by retail network pharmacies	`PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies`	$90.89B	USD	2 Qtrs
Insurance benefits paid	`PaymentsforInsuranceBenefits`	$33.92B	USD	2 Qtrs
Insurance benefits paid	`PaymentsforInsuranceBenefits`	$31.25B	USD	2 Qtrs
Cash paid to other suppliers and employees	`PaymentsToSuppliersAndEmployees`	$14.90B	USD	2 Qtrs
Cash paid to other suppliers and employees	`PaymentsToSuppliersAndEmployees`	$15.12B	USD	2 Qtrs
Interest and investment income received	`ProceedsFromInterestAndDividendsReceived`	$200.00M	USD	2 Qtrs
Interest and investment income received	`ProceedsFromInterestAndDividendsReceived`	$394.00M	USD	2 Qtrs
Interest paid	`InterestPaidNet`	$1.26B	USD	2 Qtrs
Interest paid	`InterestPaidNet`	$1.15B	USD	2 Qtrs
Income taxes paid	`IncomeTaxesPaidNet`	$1.55B	USD	2 Qtrs
Income taxes paid	`IncomeTaxesPaidNet`	$1.89B	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$9.01B	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$8.74B	USD	2 Qtrs
Proceeds from sales and maturities of investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$3.95B	USD	2 Qtrs
Proceeds from sales and maturities of investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$4.36B	USD	2 Qtrs
Purchases of investments	`PaymentsToAcquireInvestments`	$5.57B	USD	2 Qtrs
Purchases of investments	`PaymentsToAcquireInvestments`	$5.01B	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.46B	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.31B	USD	2 Qtrs
Acquisitions (net of cash acquired)	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$108.00M	USD	2 Qtrs
Acquisitions (net of cash acquired)	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$125.00M	USD	2 Qtrs
Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,807)	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	-	USD	2 Qtrs
Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,807)	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	$-1.94B	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-72.00M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-54.00M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-4.12B	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.97B	USD	2 Qtrs
Repayments of long-term debt	`RepaymentsOfLongTermDebt`	$5.42B	USD	2 Qtrs
Repayments of long-term debt	`RepaymentsOfLongTermDebt`	$1.53B	USD	2 Qtrs
Repurchase of common stock	`PaymentsForRepurchaseOfCommonStock`	$2.00B	USD	2 Qtrs
Repurchase of common stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	2 Qtrs
Dividends paid	`PaymentsOfDividends`	$1.31B	USD	2 Qtrs
Dividends paid	`PaymentsOfDividends`	$1.46B	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$330.00M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$348.00M	USD	2 Qtrs
Payments for taxes related to net share settlement of equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$159.00M	USD	2 Qtrs
Payments for taxes related to net share settlement of equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$329.00M	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-139.00M	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$46.00M	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-6.51B	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-5.11B	USD	2 Qtrs
Net decrease in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-228.00M	USD	2 Qtrs
Net decrease in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-747.00M	USD	2 Qtrs
Cash, cash equivalents and restricted cash at the beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.46B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.69B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.30B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.04B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.46B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.69B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.30B	USD	Point-in-time
Cash, cash equivalents and restricted cash at the end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.04B	USD	Point-in-time
Net income	`ProfitLoss`	$5.27B	USD	2 Qtrs
Net income	`ProfitLoss`	$5.01B	USD	2 Qtrs
Net income	`ProfitLoss`	$2.31B	USD	1 Quarter
Net income	`ProfitLoss`	$2.96B	USD	1 Quarter
Net income	`ProfitLoss`	$2.79B	USD	1 Quarter
Net income	`ProfitLoss`	$2.22B	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$2.26B	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$2.14B	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$232.00M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$236.00M	USD	2 Qtrs
Gain on sale of subsidiary	`GainLossOnSaleOfBusiness`	-	USD	1 Quarter
Gain on sale of subsidiary	`GainLossOnSaleOfBusiness`	$225.00M	USD	2 Qtrs
Gain on sale of subsidiary	`GainLossOnSaleOfBusiness`	$225.00M	USD	1 Quarter
Gain on sale of subsidiary	`GainLossOnSaleOfBusiness`	-	USD	2 Qtrs
Deferred income taxes and other noncash items	`Deferredincometaxesandothernoncashitems`	$-281.00M	USD	2 Qtrs
Deferred income taxes and other noncash items	`Deferredincometaxesandothernoncashitems`	$-370.00M	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$2.69B	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$2.38B	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$-469.00M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$-1.52B	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$219.00M	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$325.00M	USD	2 Qtrs
Accounts payable and pharmacy claims and discounts payable	`IncreaseDecreaseInAccountsPayable`	$1.70B	USD	2 Qtrs
Accounts payable and pharmacy claims and discounts payable	`IncreaseDecreaseInAccountsPayable`	$2.03B	USD	2 Qtrs
Health care costs payable and other insurance liabilities	`IncreaseDecreaseInInsuranceLiabilities`	$1.47B	USD	2 Qtrs
Health care costs payable and other insurance liabilities	`IncreaseDecreaseInInsuranceLiabilities`	$104.00M	USD	2 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$903.00M	USD	2 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$879.00M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$9.01B	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$8.74B	USD	2 Qtrs

Stockholders Equity 58 line items

Line Item	Tag	Value	Unit	Period
Treasury shares held in trust (in shares)	`TreasuryStockSharesHeldinTrust`	1.00M	shares	Point-in-time
Treasury shares held in trust (in shares)	`TreasuryStockSharesHeldinTrust`	1.00M	shares	Point-in-time
Treasury shares held in trust (in shares)	`TreasuryStockSharesHeldinTrust`	1.00M	shares	Point-in-time
Treasury shares held in trust (in shares)	`TreasuryStockSharesHeldinTrust`	1.00M	shares	Point-in-time
Treasury shares held in trust (in shares)	`TreasuryStockSharesHeldinTrust`	1.00M	shares	Point-in-time
Treasury shares held in trust (in shares)	`TreasuryStockSharesHeldinTrust`	1.00M	shares	Point-in-time
Treasury share held in trust	`TreasuryStockValueSharesHeldInTrust`	$29.00M	USD	Point-in-time
Treasury share held in trust	`TreasuryStockValueSharesHeldInTrust`	$29.00M	USD	Point-in-time
Treasury share held in trust	`TreasuryStockValueSharesHeldInTrust`	$29.00M	USD	Point-in-time
Treasury share held in trust	`TreasuryStockValueSharesHeldInTrust`	$29.00M	USD	Point-in-time
Treasury share held in trust	`TreasuryStockValueSharesHeldInTrust`	$29.00M	USD	Point-in-time
Treasury share held in trust	`TreasuryStockValueSharesHeldInTrust`	$29.00M	USD	Point-in-time
Common stock	`CommonStockValue`	$17.00M	USD	Point-in-time
Common stock	`CommonStockValue`	$17.00M	USD	Point-in-time
Common stock	`CommonStockValue`	$17.00M	USD	Point-in-time
Common stock	`CommonStockValue`	$17.00M	USD	Point-in-time
Common stock	`CommonStockValue`	$17.00M	USD	Point-in-time
Common stock	`CommonStockValue`	$18.00M	USD	Point-in-time
Balance at beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$75.51B	USD	Point-in-time
Balance at beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$69.70B	USD	Point-in-time
Balance at beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$74.14B	USD	Point-in-time
Balance at beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$73.56B	USD	Point-in-time
Balance at beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$71.16B	USD	Point-in-time
Balance at beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$75.38B	USD	Point-in-time
Net income	`ProfitLoss`	$5.27B	USD	2 Qtrs
Net income	`ProfitLoss`	$5.01B	USD	2 Qtrs
Net income	`ProfitLoss`	$2.31B	USD	1 Quarter
Net income	`ProfitLoss`	$2.96B	USD	1 Quarter
Net income	`ProfitLoss`	$2.79B	USD	1 Quarter
Net income	`ProfitLoss`	$2.22B	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-1.16B	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-244.00M	USD	2 Qtrs
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$148.00M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-392.00M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-798.00M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-1.95B	USD	2 Qtrs
Stock option activity, stock awards and other	`StockIssuedDuringPeriodValueStockOptionsExercised`	$300.00M	USD	1 Quarter
Stock option activity, stock awards and other	`StockIssuedDuringPeriodValueStockOptionsExercised`	$214.00M	USD	1 Quarter
Stock option activity, stock awards and other	`StockIssuedDuringPeriodValueStockOptionsExercised`	$197.00M	USD	1 Quarter
Stock option activity, stock awards and other	`StockIssuedDuringPeriodValueStockOptionsExercised`	$268.00M	USD	1 Quarter
Purchase of treasury shares, net of ESPP issuances	`TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance`	$1.97B	USD	1 Quarter
Purchase of treasury shares, net of ESPP issuances	`TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance`	$150.00M	USD	1 Quarter
Purchase of treasury shares, net of ESPP issuances	`TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance`	$267.00M	USD	1 Quarter
ESPP issuances, net of purchase of treasury shares	`ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod`	$76.00M	USD	1 Quarter
Common stock dividends	`DividendsCommonStock`	$655.00M	USD	1 Quarter
Common stock dividends	`DividendsCommonStock`	$660.00M	USD	1 Quarter
Common stock dividends	`DividendsCommonStock`	$729.00M	USD	1 Quarter
Common stock dividends	`DividendsCommonStock`	$730.00M	USD	1 Quarter
Other increases (decreases) in noncontrolling interests	`NoncontrollinginterestOtherPeriodIncreaseDecrease`	$-1.00M	USD	1 Quarter
Other increases (decreases) in noncontrolling interests	`NoncontrollinginterestOtherPeriodIncreaseDecrease`	$1.00M	USD	1 Quarter
Other increases (decreases) in noncontrolling interests	`NoncontrollinginterestOtherPeriodIncreaseDecrease`	$2.00M	USD	1 Quarter
Other increases (decreases) in noncontrolling interests	`NoncontrollinginterestOtherPeriodIncreaseDecrease`	$3.00M	USD	1 Quarter
Balance at end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$75.51B	USD	Point-in-time
Balance at end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$69.70B	USD	Point-in-time
Balance at end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$74.14B	USD	Point-in-time
Balance at end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$73.56B	USD	Point-in-time
Balance at end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$71.16B	USD	Point-in-time
Balance at end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$75.38B	USD	Point-in-time

Comprehensive Income 40 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$5.27B	USD	2 Qtrs
Net income	`ProfitLoss`	$5.01B	USD	2 Qtrs
Net income	`ProfitLoss`	$2.31B	USD	1 Quarter
Net income	`ProfitLoss`	$2.96B	USD	1 Quarter
Net income	`ProfitLoss`	$2.79B	USD	1 Quarter
Net income	`ProfitLoss`	$2.22B	USD	1 Quarter
Net unrealized investment gains (losses)	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$149.00M	USD	1 Quarter
Net unrealized investment gains (losses)	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-237.00M	USD	2 Qtrs
Net unrealized investment gains (losses)	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-1.97B	USD	2 Qtrs
Net unrealized investment gains (losses)	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-813.00M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$2.00M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00M	USD	1 Quarter
Net cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$15.00M	USD	1 Quarter
Net cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-3.00M	USD	1 Quarter
Net cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$12.00M	USD	2 Qtrs
Net cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-7.00M	USD	2 Qtrs
Pension and other postretirement benefits	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-1.00M	USD	2 Qtrs
Pension and other postretirement benefits	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-1.00M	USD	2 Qtrs
Pension and other postretirement benefits	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-1.00M	USD	1 Quarter
Pension and other postretirement benefits	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-1.00M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-1.16B	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-244.00M	USD	2 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$148.00M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-392.00M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-798.00M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-1.95B	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$3.32B	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$2.94B	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$4.77B	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$2.16B	USD	1 Quarter
Comprehensive income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$8.00M	USD	1 Quarter
Comprehensive income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$10.00M	USD	1 Quarter
Comprehensive income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$11.00M	USD	2 Qtrs
Comprehensive income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$9.00M	USD	2 Qtrs
Comprehensive income attributable to CVS Health	`ComprehensiveIncomeNetOfTax`	$2.93B	USD	1 Quarter
Comprehensive income attributable to CVS Health	`ComprehensiveIncomeNetOfTax`	$4.76B	USD	2 Qtrs
Comprehensive income attributable to CVS Health	`ComprehensiveIncomeNetOfTax`	$2.15B	USD	1 Quarter
Comprehensive income attributable to CVS Health	`ComprehensiveIncomeNetOfTax`	$3.31B	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.